Vor Biopharma Inc (VOR)

$2.20 +0.03 (1.38%)
Market Cap 274.91M
Revenue (ttm) 0.00
Net Income (ttm) -116.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,105,400
Avg Vol 21,875,471
Day's Range N/A - N/A
Shares Out 124.96M
Stochastic %K 38%
Beta 2.04
Analysts Sell
Price Target $1.18

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
100 Cambridgepark Drive, Suite 101, Cambridge, United States
CAPITALWHISPERER
CAPITALWHISPERER Jul. 28 at 8:20 AM
$NCNA $IXHL $VOR $KLTO $BMNR
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 28 at 7:51 AM
$NCNA $IXHL $VOR $KLTO $BMNR
1 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 28 at 1:36 AM
$NCNA $1 this week coming. $10.76 last run. 59m warrants cancelled. 0 dilution. heavily shorted. short squeeze will be epic. another bio monster. FDA news for cancer can hit anytime. Multiday runner. BOOM BOOM like my other calls. $IXHL my call at $0.08 hit $1.73 $VOR my call at $0.13 hit $3.29 $KLTO my call at $0.19 hit $3.91 $BMNR my call at $12 hit $161
2 · Reply
dbr_island
dbr_island Jul. 26 at 3:47 PM
$LFWD $VOR just trying to help my followers
2 · Reply
YakoCapital
YakoCapital Jul. 25 at 7:37 PM
$VOR Shirt squeeze play right here, 14 Mil shares short. With a good market we will be making bread
1 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 25 at 7:14 PM
$NCNA $VOR
1 · Reply
ProfessorDman1
ProfessorDman1 Jul. 25 at 6:54 PM
SMX > 3s better closing bell 🔔 > $5+ next week $10-$20 range run .. Take notes from $BMNR $VOR $OPEN $SBET $MCVT
0 · Reply
Mastertrader80
Mastertrader80 Jul. 25 at 6:38 PM
$IXHL completely agree,,, at this point im just here for fun and to wind the bears up,,, doesnt evan matter what the daily sp is ,, all signs lead to positive results ,, i dont even care about the illegal insider trading ah , i know this stock will be $6 plus on news the stocks below all had massive gains on news ! and their news wasnt in the slightest bit as bullish as what ixhl are working on 10billion dollar industry with zero competitors ! $ABVX $PROK $VOR $WOLF
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 25 at 6:36 PM
$NCNA $0.07 reminds me of $VOR my call at $0.13 hit $3.29
0 · Reply
YakoCapital
YakoCapital Jul. 25 at 6:20 PM
$VOR 14 million shares are shorted. Wait for a squeeze! https://www.nasdaq.com/market-activity/stocks/vor/short-interest
0 · Reply
Latest News on VOR
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 21, 2025, 8:30 AM EDT - 6 days ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 18, 2025, 4:00 PM EDT - 9 days ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 17, 2025, 8:30 AM EDT - 10 days ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 10, 2025, 4:00 PM EDT - 17 days ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:00 PM EDT - 26 days ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 30, 2025, 2:31 PM EDT - 27 days ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 4 weeks ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Jun 25, 2025, 4:45 PM EDT - 4 weeks ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025, 8:30 AM EDT - 2 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 4:05 PM EDT - 4 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 13, 2025, 8:00 AM EST - 5 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 6 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Jan 8, 2025, 9:00 AM EST - 7 months ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 7 months ago

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Dec 9, 2024, 7:30 AM EST - 8 months ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 30, 2024, 7:00 AM EDT - 10 months ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 6, 2024, 9:35 AM EDT - 11 months ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Sep 5, 2024, 4:01 PM EDT - 11 months ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio to Participate in Upcoming Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 11 months ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Jan 17, 2024, 4:01 PM EST - 1 year ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Nov 27, 2023, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Nov 9, 2023, 4:01 PM EST - 1 year ago

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 7, 2023, 4:05 PM EST - 1 year ago

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Nov 2, 2023, 9:01 AM EDT - 1 year ago

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

Jul 5, 2023, 8:51 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

CBUS LUCY

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Jun 9, 2023, 7:30 AM EDT - 2 years ago

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Mar 27, 2023, 3:13 PM EDT - 2 years ago

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Feb 16, 2023, 12:00 PM EST - 2 years ago

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Jan 19, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Jan 12, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

Dec 7, 2022, 7:45 AM EST - 2 years ago

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Dec 7, 2022, 7:30 AM EST - 2 years ago

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Nov 10, 2022, 4:15 PM EST - 2 years ago

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Vor Bio Appoints Eyal C. Attar, M.D.

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Appoints Eyal C. Attar, M.D.

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Oct 11, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

Sep 28, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Aug 11, 2022, 4:15 PM EDT - 3 years ago

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Jun 10, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

May 12, 2022, 4:15 PM EDT - 3 years ago

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

Vor to Participate in Two Upcoming Investor Conferences

May 5, 2022, 8:00 AM EDT - 3 years ago

Vor to Participate in Two Upcoming Investor Conferences

CAPITALWHISPERER
CAPITALWHISPERER Jul. 28 at 8:20 AM
$NCNA $IXHL $VOR $KLTO $BMNR
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 28 at 7:51 AM
$NCNA $IXHL $VOR $KLTO $BMNR
1 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 28 at 1:36 AM
$NCNA $1 this week coming. $10.76 last run. 59m warrants cancelled. 0 dilution. heavily shorted. short squeeze will be epic. another bio monster. FDA news for cancer can hit anytime. Multiday runner. BOOM BOOM like my other calls. $IXHL my call at $0.08 hit $1.73 $VOR my call at $0.13 hit $3.29 $KLTO my call at $0.19 hit $3.91 $BMNR my call at $12 hit $161
2 · Reply
dbr_island
dbr_island Jul. 26 at 3:47 PM
$LFWD $VOR just trying to help my followers
2 · Reply
YakoCapital
YakoCapital Jul. 25 at 7:37 PM
$VOR Shirt squeeze play right here, 14 Mil shares short. With a good market we will be making bread
1 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 25 at 7:14 PM
$NCNA $VOR
1 · Reply
ProfessorDman1
ProfessorDman1 Jul. 25 at 6:54 PM
SMX > 3s better closing bell 🔔 > $5+ next week $10-$20 range run .. Take notes from $BMNR $VOR $OPEN $SBET $MCVT
0 · Reply
Mastertrader80
Mastertrader80 Jul. 25 at 6:38 PM
$IXHL completely agree,,, at this point im just here for fun and to wind the bears up,,, doesnt evan matter what the daily sp is ,, all signs lead to positive results ,, i dont even care about the illegal insider trading ah , i know this stock will be $6 plus on news the stocks below all had massive gains on news ! and their news wasnt in the slightest bit as bullish as what ixhl are working on 10billion dollar industry with zero competitors ! $ABVX $PROK $VOR $WOLF
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 25 at 6:36 PM
$NCNA $0.07 reminds me of $VOR my call at $0.13 hit $3.29
0 · Reply
YakoCapital
YakoCapital Jul. 25 at 6:20 PM
$VOR 14 million shares are shorted. Wait for a squeeze! https://www.nasdaq.com/market-activity/stocks/vor/short-interest
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 25 at 3:51 PM
$SMX lol 😂 $3+ tonight and $10+ next week .. Remeber $VOR $BMNR $SBET $VLCN my recent 2000%-4000%+ ideas swing from bottom
1 · Reply
SniperG123
SniperG123 Jul. 25 at 3:29 PM
$VOR where is @Ultra_Calls today?
0 · Reply
alpine2001
alpine2001 Jul. 25 at 1:57 PM
$WLGS next we will hit $0.20 and then $0.30 and more $1.00 next $VOR
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 25 at 1:28 PM
$ABP reminds me of $VOR my call at $0.13 hit $3.29 with 100M float. ABP has only 20M float.
0 · Reply
MGeronimo
MGeronimo Jul. 25 at 1:09 PM
$VOR new 52 week high coming soon
0 · Reply
Savinetti
Savinetti Jul. 24 at 8:45 PM
$VOR i have 100 share at 0.16 wish i had 100000
1 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 8:13 PM
$BMNR $JFBR $SBET $VLCN $VOR ( JFBR is next for $20-$50+ range runner ) 🏃‍♀️
0 · Reply
YakoCapital
YakoCapital Jul. 24 at 8:03 PM
$VOR 40% of the float is shorted, wait for the squeeze. It will be huge
1 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 24 at 7:55 PM
$OPI $IXHL $VOR $KLTO $CYN
1 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 24 at 7:44 PM
$OPI $1 AH coming. $67M cash. $3.5B assets. $15.30 book per share. MULTIDAY RUNNER. BOOM BOOM. $IXHL my call at $0.08 to $1.63 $VOR my call at $0.13 to $3.29 $KLTO my call at $0.19 to $3.91 $CYN my call at $4.90 to $40
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 24 at 7:03 PM
$OPI $IXHL $VOR $KLTO $CYN
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 6:27 PM
$BMNR $JFBR $SBET $VLCN $VOR (JFBR double digits run in making ) ⏰⏰✍️✅💵
0 · Reply